NCT03062618

A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis

Randomized, Double Blind, Placebo Controlled, Incomplete Crossover Single Oral Dose Escalation of PRCL-02 in Normal Healthy Volunteers (Part A) and Multiple Oral Dose Escalation in Normal Healthy Volunteers (Part B) and in Chronic Plaque Psoriasis Patients (Part C)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: PRCL Research Inc. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study consists of three parts: single oral dose escalation in healthy volunteers (Part A), and multiple oral dose escalations in healthy volunteers (Part B) and in participants with chronic plaque psoriasis (Part C)

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	PRCL-02	Oral tablet(s) administered with water
DRUG	Placebo Oral Tablet	Administered with water

Timeline

• Start date: 2017-02-20
• Primary completion: 2018-02-08
• Completion: 2018-02-08
• First posted: 2017-02-23
• Last updated: 2018-03-07

Locations

6 sites across 1 country: Canada

Regulatory

• FDA-regulated drug study